WuXi Biologics Achieves Outstanding ESG Recognition for Five Years Running

In a significant achievement, WuXi Biologics, a premier global Contract Research, Development, and Manufacturing Organization (CRDMO), has been awarded the title of a 2025 Industry and Regional ESG Top-Rated Company by the influential research firm Morningstar Sustainalytics. This marks the fifth consecutive year that WuXi Biologics has ranked among the top performers in Environmental, Social, and Governance (ESG) risk ratings across the pharmaceutical sector.

High Ratings in Sustainability Practices

Morningstar Sustainalytics evaluates more than 15,000 companies across 42 industries, issuing badges to those demonstrating exceptional ESG practices. WuXi Biologics has impressively secured its place in the top 1% of the pharmaceutical industry for sustainability efforts. The recognition underscores the company’s dedication to fostering sustainable practices while also driving innovation in biologics development.

Dr. Chris Chen, the CEO of WuXi Biologics, expressed his satisfaction with this accolade. He stated, "We are very pleased to once again receive this honor from Morningstar Sustainalytics. It is a reflection and recognition of our ongoing commitment to enhancing sustainability capabilities." He emphasized that WuXi Biologics is not only focused on its own ESG excellence but actively helps partners worldwide meet their sustainability commitments by embracing responsible practices throughout the value chain.

Achievements and Innovations

In recent years, the company has made remarkable progress with its ESG strategies. Its achievements include being spotlighted in the UNGC's collection of 20 case examples of sustainable development, showing its leading edge in environmentally friendly biologics solutions. Furthermore, WuXi Biologics has earned an MSCI AAA Rating, been included in the Dow Jones Sustainability Indices for two successive years, and has been awarded a Platinum Medal by EcoVadis.

Continuing to solidify its reputation, WuXi Biologics was also named an A list participant in CDP Water Security and received an esteemed "A-" score for its response to climate change efforts. The company is a constituent of the FTSE4Good Index Series and appears in the Hang Seng ESG 50 Index.

Committing to a Sustainable Future

WuXi Biologics views its ESG responsibilities as a crucial part of its business strategy. The organization operates facilities that utilize next-generation biomanufacturing technologies and source clean energy in their manufacturing processes. The establishment of an ESG committee, helmed by the CEO, further solidifies their commitment, demonstrating proactive governance in implementing comprehensive ESG strategies.

With over 12,000 employees spread across multiple countries including China, the US, Ireland, Germany, and Singapore, WuXi Biologics is well-positioned to support clients in biotechnological projects. The company is currently managing 817 integrated client projects and has embarked on 21 in commercial manufacturing, excluding COVID-related projects, signifying an active role in transforming the landscape of biologics.

As WuXi Biologics continues to lead in the CRDMO sector, it sets a benchmark for the industry, manifesting how thoughtful integration of sustainability into business practices can yield positive outcomes not just for the company, but for stakeholders and the community at large.

To learn more about WuXi Biologics and its commitment to ESG principles, visit their official website at WuXi Biologics.